Abstract
Diabetic Kidney Disease (DKD) is one of the major complications of Diabetes Mellitus (DM) and is currently the most common cause of End-Stage Renal Disease (ESRD) worldwide. Traditionally, DKD is considered a disease which has nothing to do with the immune system, and the pathogenesis is mainly characterized to be metabolic disturbance. Recent growing evidence indicates immunologic and inflammatory mechanisms in the development and progression of DKD. This overview of macrophages, dendritic cells, T lymphocytes, B lymphocytes, neutrophils and mast cells is closely involved in the pathologic process of DKD, with more emphasis on the leucocyte accumulation and related molecular mechanisms. Moreover, the potential contributions of these immune cells to renal injury will also be discussed. Specifically, these findings help to identify new potential therapeutic targets of DKD. Future preclinical and clinical studies might translate these exciting findings into clinical applications.
Keywords: Diabetic kidney disease, Immune cells, Pathogenesis, Therapeutic methods, End stage renal disease, Diabetes mellitus.
Current Gene Therapy
Title:Role of Immune Cells in Diabetic Kidney Disease
Volume: 17 Issue: 6
Author(s): Xiaoqian Yang and Shan Mou*
Affiliation:
- Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai 200127,China
Keywords: Diabetic kidney disease, Immune cells, Pathogenesis, Therapeutic methods, End stage renal disease, Diabetes mellitus.
Abstract: Diabetic Kidney Disease (DKD) is one of the major complications of Diabetes Mellitus (DM) and is currently the most common cause of End-Stage Renal Disease (ESRD) worldwide. Traditionally, DKD is considered a disease which has nothing to do with the immune system, and the pathogenesis is mainly characterized to be metabolic disturbance. Recent growing evidence indicates immunologic and inflammatory mechanisms in the development and progression of DKD. This overview of macrophages, dendritic cells, T lymphocytes, B lymphocytes, neutrophils and mast cells is closely involved in the pathologic process of DKD, with more emphasis on the leucocyte accumulation and related molecular mechanisms. Moreover, the potential contributions of these immune cells to renal injury will also be discussed. Specifically, these findings help to identify new potential therapeutic targets of DKD. Future preclinical and clinical studies might translate these exciting findings into clinical applications.
Export Options
About this article
Cite this article as:
Yang Xiaoqian and Mou Shan *, Role of Immune Cells in Diabetic Kidney Disease, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214100351
DOI https://dx.doi.org/10.2174/1566523218666180214100351 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Nmr Studies Of The Prionogenic Peptide Derived From Sup35 Protein
Protein & Peptide Letters Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Hypothalamic AMP-activated Protein Kinase as a Regulator of Food Intake and Energy Balance
CNS & Neurological Disorders - Drug Targets Diabetic Foot and Exercise Therapy: Step by Step The Role of Rigid Posture and Biomechanics Treatment
Current Diabetes Reviews The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents on Diacylglycerol Production and Applications
Recent Patents on Chemical Engineering Angiotensin-TGF-β1 Crosstalk in Human Idiopathic Pulmonary Fibrosis:Autocrine Mechanisms in Myofibroblasts and Macrophages
Current Pharmaceutical Design The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Radiocontrast Nephropathy: Progress not Prevention
Current Cardiology Reviews The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Trans-Plasma Membrane Electron Transport in Human Blood Platelets
Mini-Reviews in Medicinal Chemistry The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism Preparation and Evaluation of Buccal Bioadhesive Tablets Containing Clotrimazole
Current Drug Delivery Understanding the Mechanism and Prevention of Arterial Occlusive Thrombus Formation by Anti-Platelet Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents